Please login to the form below

Not currently logged in
Email:
Password:

PE

This page shows the latest PE news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

NICE recommends Daiichi Sankyo's Lixiana for DVT and PE. Institute's final guidance concludes the novel oral anticoagulant is cost effective. ... NICE concluded that Lixiana was a cost-effective use of NHS resources for deep vein thrombosis (DVT) and

Latest news

More from news
Approximately 2 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Earlier in the month the private equity (PE) firm Cinven offered 56 a share to acquire Stada but this has been topped by a binding offer from another PE company, Advent ... A third suitor is believed to be another PE firm, Bain Capital.

  • Pharma deals during November 2014 Pharma deals during November 2014

    It's understood that a number of PE firms are set to acquire the diabetes portfolio, which includes Contour (the blood glucose meter) for $2.5bn.

  • Pharma deals during October 2013 Pharma deals during October 2013

    Overall there was a somewhat eclectic mix of companies featuring in the deals reported and interestingly private equity (PE) companies were involved in several of the transactions. ... The other major deal featuring PE is the acquisition of Acino by

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    2012. Rivaroxaban is also awaiting US approval for the treatment of VTE or PE, and for long-term prevention of recurrent VTE.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Global Corporate Divestment Study

    The study is based on interviews with 900 global C-suite executives and 100 PE executives, plus external market data.

  • EY Life Sciences

    The study is based on interviews with 900 global C-suite executives and 100 PE executives, plus external market data.

  • FCB Halesway

    Eczema. BMS. Metastatic melanoma. Lung cancer. Boehringer Ingelheim. VTE prophylaxis. DVT/PE.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics